Production of recombinant Zika virus envelope protein by airlift bioreactor as a new subunit vaccine platform
Hernan H. M. Da Costa, Monica Bielavsky, Diego J. B. Orts, Sergio Araujo, Patrícia P. Adriani, Juliana S. Nogueira, Renato M. Astray, Ramendra P. Pandey, Marcelo Lancellotti, Jair P. Cunha-Junior, Carlos R. Prudencio
ARTIGO
Inglês
Agradecimentos: We thank Daniela Santoro Rosa from the Laboratory of Experimental Vaccines (LaVEx), Federal University of São Paulo (Unifesp), São Paulo, Brazil, for donating the plasmid encoding the rEZIKV. This work was supported by grants from the National Council for Scientific and Technological...
Ver mais
Agradecimentos: We thank Daniela Santoro Rosa from the Laboratory of Experimental Vaccines (LaVEx), Federal University of São Paulo (Unifesp), São Paulo, Brazil, for donating the plasmid encoding the rEZIKV. This work was supported by grants from the National Council for Scientific and Technological Development (CNPq Grant ID 130843/2020-2 to H.H.M.d.C., and 440812/2016-0 to C.R.P.), Ministry of Health, Special Health Fund for Mass Immunization and Disease Control of the State Department of Health of the State of São Paulo (FESIMA), Coordination for the Improvement of Higher Education Personnel (CAPES Grant ID 88887.703323/2022-00 to H.H.M.d.C., and 88881.130804/2016–01 to C.R.P.), São Paulo Research Foundation (FAPESP Grant ID 2022/07256-0 to D.J.B.O., and 2021/11936-3, 2017/50333-7 to C.R.P.)
Ver menos
Abstract: The Zika Virus (ZIKV) is an emerging arbovirus of great public health concern, particularly in the Americas after its last outbreak in 2015. There are still major challenges regarding disease control, and there is no ZIKV vaccine currently approved for human use. Among many different...
Ver mais
Abstract: The Zika Virus (ZIKV) is an emerging arbovirus of great public health concern, particularly in the Americas after its last outbreak in 2015. There are still major challenges regarding disease control, and there is no ZIKV vaccine currently approved for human use. Among many different vaccine platforms currently under study, the recombinant envelope protein from Zika Virus (rEZIKV) constitutes an alternative option for vaccine development and has great potential for monitoring ZIKV infection and antibody response. This study describes a method to obtain a bioactive and functional rEZIKV using an E. coli expression system, with the aid of a 5-L airlift bioreactor and following an automated fast protein liquid chromatography (FPLC) protocol, capable of obtaining high yields of approximately 20 mg of recombinant protein per liter of bacterium cultures. The purified rEZIKV presented preserved antigenicity and immunogenicity. Our results show that the use of an airlift bioreactor for the production of rEZIKV is ideal for establishing protocols and further research on ZIKV vaccines bioprocess, representing a promising system for the production of a ZIKV envelope recombinant protein-based vaccine candidate
Ver menos
CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ
440812/2016-0; 130843/2020-2
COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPES
88881.130804/2016–01; 88887.703323/2022-00
FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP
2017/50333-7; 2021/11936-3; 2022/07256-0
Aberto
Bielavsky, Monica
Autor
Orts, Diego Jose Belato
Autor
DOI: https://doi.org/10.3390/ijms241813955
Texto completo: https://www.mdpi.com/1422-0067/24/18/13955
Production of recombinant Zika virus envelope protein by airlift bioreactor as a new subunit vaccine platform
Hernan H. M. Da Costa, Monica Bielavsky, Diego J. B. Orts, Sergio Araujo, Patrícia P. Adriani, Juliana S. Nogueira, Renato M. Astray, Ramendra P. Pandey, Marcelo Lancellotti, Jair P. Cunha-Junior, Carlos R. Prudencio
Production of recombinant Zika virus envelope protein by airlift bioreactor as a new subunit vaccine platform
Hernan H. M. Da Costa, Monica Bielavsky, Diego J. B. Orts, Sergio Araujo, Patrícia P. Adriani, Juliana S. Nogueira, Renato M. Astray, Ramendra P. Pandey, Marcelo Lancellotti, Jair P. Cunha-Junior, Carlos R. Prudencio
Fontes
International journal of molecular sciences (Fonte avulsa) |